Andere Sprachen Clearside Biomedical, Inc.

Aktien

A2ALP6

US1850631045

CLSD

Verzögert Nasdaq Andere Börsenplätze 17:43:48 29.04.2024			% 5 Tage	% 1. Jan.
1,32 ^USD	-1,49 %		-6,38 %	+12,82 %

16.04.	Clearside Biomedical, Inc. ernennt Anthony S. Gibney zum Mitglied des Board of Directors	CI
18.03.	Clearside Biomedical ernennt Victor Chong zum Chief Medical Officer	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors	16.04.
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	16.04.
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Clearside Biomedical Names Victor Chong Chief Medical Officer	18.03.
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18.03.
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18.03.
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12.03.
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024	29.02.
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering	07.02.
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO	22.01.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14.12.
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14.12.
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update	13.11.
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference	08.11.
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting	07.11.
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	03.11.
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®	03.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clearside Biomedical, Inc.

Aktien

A2ALP6

US1850631045

CLSD

Andere Sprachen

Filter